Our Solentim portfolio of innovative technologies is designed to accelerate and streamline cell line development workflows from initial discovery to scale-up, providing total consistency across the workflow and a 'double lock' of assurance for a successful IND submission.
White Paper
Assurance of Clonality: a key regulatory requirement for biotherapeutics
Ensuring clonal origin of production cell lines is a critical step in the manufacturing of advanced biotherapeutics. Innovative devices help increase the efficiency of the cloning process and bring image-based assurance of clonality.
Clonal derivation of cell lines used in biotherapeutics manufacturing is a critical quality attribute and a requirement for regulatory submission. State-of-the art technologies can help you optimize the isolation of single cells and provide the proof of clonality health authorities require.
In this White Paper, you will learn:
Verified In-Situ Plate Seeding (VIPS) accelerates single cell seeding workflows while also ensuring clonality and driving discovery and development of antibody, cell & gene therapies, and iPSC-based studies.
Next generation cell culture supplements are proprietary animal component-free and confer major growth and survival advantages within cell line development for CHO, HEK and iPSC cells.
The integration of Advanced Instruments osmometers and Solentim products for Cell Line Development offers customers a broad range of innovative technologies for optimizing their bioprocessing workflow.
